Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug consisting of three active ingredients—albuterol, budesonide, and formoterol—delivered via inhalation. Albuterol is a short-acting beta-2 adrenergic agonist (SABA) that acts as a bronchodilator to quickly relax airway smooth muscle and relieve acute bronchospasm. Budesonide is an inhaled corticosteroid (ICS) that reduces inflammation in the airways, helping to prevent asthma attacks and control chronic symptoms. Formoterol is a long-acting beta-2 adrenergic agonist (LABA), providing prolonged bronchodilation for maintenance therapy in asthma or chronic obstructive pulmonary disease (COPD). The combination aims to provide both rapid symptom relief and ongoing anti-inflammatory control for respiratory diseases such as asthma or COPD.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on albuterol + budesonide + formoterol.